Cell-free nucleic acids, which include cell-free DNA (cfDNA) and cell-free RNA (cfRNA), circulate freely in the bloodstream and other bodily fluids. They carry molecular signatures that originate from dying cells throughout the body, delivering a rich reservoir of information about cellular states and tissue health. Unlike traditional needle biopsies, cfNA liquid biopsies circumvent the need for invasive procedures, making routine monitoring more feasible and less burdensome for patients. However, this great advantage comes with a caveat: the biological signals captured in cfNA mixtures represent heterogeneous cellular origins, which complicates efforts to resolve disease-specific cellular contributions.

The reviewed article provides a comprehensive overview of how recent technological and computational innovations have converged to address this intrinsic challenge of cell type resolution in cfNA analysis. Central to this progress are two pillars: either leveraging cell type-specific DNA methylation patterns, fragmentation signatures, or nucleosome positioning in cfDNA, and the orthogonal but increasingly accessible profiling of cfRNA. Together, cfDNA and cfRNA provide complementary molecular perspectives, from genetic and epigenetic alterations to active gene expression, enabling multidimensional views of cellular contributions within liquid biopsies.

A particularly transformative dimension highlighted in the review is the integration of single-cell transcriptomics data. Single-cell RNA sequencing (scRNA-seq) has revolutionized our molecular understanding by revealing detailed gene expression maps across myriad human cell types. By harnessing these high-resolution reference atlases, computational algorithms can deconvolute cfRNA signals with unprecedented fidelity, teasing apart the complex cellular mixtures that comprise cfNAs. This synergy between massive single-cell datasets and sophisticated deconvolution models paves the way for more accurate and clinically actionable interpretations of liquid biopsy profiles.

The authors discuss the diverse landscape of computational frameworks that have been developed to infer cell type contributions from cfNA data. These methods vary in complexity, ranging from classical regression techniques to deep learning approaches, each tailored to handle the unique challenges posed by cfDNA and cfRNA modalities. Notably, methylation-based deconvolution leverages the tissue-specific DNA methylation signatures preserved in cfDNA, while transcriptomic deconvolution relies on cfRNA abundance profiles aligned to cell type reference signatures.

Furthermore, the review underscores the distinct diagnostic use cases and biological insights derivable from cfDNA versus cfRNA. cfDNA has been particularly prominent in oncology, enabling the detection of tumor-specific mutations, methylation aberrations, and chromatin organization changes. Conversely, cfRNA can illuminate dynamic transcriptional changes reflective of active cellular processes, immune responses, and potentially even temporal snapshots of developmental or pathological states. The dual interrogation of cfDNA and cfRNA thus offers a powerful multiplexing opportunity for both static and live molecular readouts.

Beyond the technical details, the authors explore practical applications of cell type inference in clinical contexts. One compelling area is cancer diagnostics, where precise cell-of-origin identification can enhance early detection and treatment stratification. Other applications extend to autoimmune diseases, organ transplant monitoring, prenatal diagnostics, and infectious disease surveillance, where noninvasive insight into tissue-specific injury and immune activation is invaluable.

The review also contemplates future directions poised to further elevate cfNA liquid biopsy capabilities. For example, improved library preparation methods, higher accuracy sequencing platforms, and expanded single-cell reference atlases across diverse populations and disease states will augment cell type resolution robustness. Additionally, real-time monitoring via longitudinal cfNA profiling holds promise for dynamic disease tracking and personalized medicine adaptation.

Nevertheless, significant challenges remain to be tackled. The heterogeneity of cfNA fragment sizes, degradation rates, and the complexity of bioinformatic deconvolution call for continued algorithmic refinement and standardization. Moreover, the biological variability stemming from individual differences, physiological conditions, and environmental influences demands rigorous validation in large, diverse cohorts before clinical translation.

Crucially, the integration of multimodal data streams—combining cfNA, proteomics, metabolomics, and imaging—may someday offer holistic, systems-level biomarker platforms. Such integrative diagnostics could transform our approach to detecting and managing diseases, from the earliest molecular alterations to overt clinical manifestations.

This seminal review in Nature Biotechnology shines a spotlight on the burgeoning paradigm of cell type inference in cfNA liquid biopsy, articulating both the remarkable progress made and the exciting horizon ahead. The fusion of cutting-edge molecular biology with innovative computational science stands to unlock new chapters in noninvasive personalized medicine, ultimately improving patient outcomes and the precision of clinical interventions.

As scientists and clinicians continue to unravel the complexities of cfNA biology and develop ever-more sensitive analytical tools, the promise of liquid biopsies as a routine, transformative diagnostic tool inches closer to reality. This work inspires a broader pursuit of understanding cell-type specific signaling cascades through minimally invasive methods, heralding a future where early disease detection and tailored therapeutic strategies are accessible, less burdensome, and profoundly informative.

The detailed discourse within this review not only advances our technical grasp of cfDNA and cfRNA analysis but also encourages interdisciplinary collaborations crucial for translating molecular insights into impactful healthcare innovations. It is a landmark contribution that paves the way for the next generation of biomarker-driven medicine.

Subject of Research: Cell type inference in cell-free nucleic acid (cfNA) liquid biopsy

Article Title: Cell type inference in cell-free nucleic acid liquid biopsy

Article References:
Vorperian, S.K., Dennis, L.M., Hupalowska, A. et al. Cell type inference in cell-free nucleic acid liquid biopsy. Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02904-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41587-025-02904-5

The core of this technological leap lies in the integration of amylin-68nαβ, a protein binder specifically engineered to interact with amylin, a peptide hormone implicated in metabolic regulation and several pathological states. Amylin itself, known for its highly dynamic and intrinsically disordered structure, has posed considerable difficulties in terms of selective enrichment from biological fluids due to its typically low endogenous concentration and susceptibility to degradation. By conjugating amylin-68nαβ to magnetic beads, the research team sought to isolate and concentrate amylin, thereby augmenting the detectable signal during subsequent LC–MS/MS analysis.

Initial experiments centered on quantifying the recovery efficiency of amylin when spiked into both human plasma and a simplified surrogate matrix composed of phosphate-buffered saline with CHAPS detergent (PBS–CHAPS). Remarkably, the amylin binders demonstrated a recovery rate of 62.2% from plasma samples, indicating a robust affinity of amylin-68nαβ under physiologically relevant conditions. Recovery from the PBS–CHAPS matrix was somewhat lower, at 53.5%, yet still clearly substantiates the binder’s potential utility in sample preparation workflows. These findings underscore the critical role of the biological milieu in modulating binder performance and emphasize the need for optimization of binding conditions tailored to complex fluids.

The platform’s deployment with LC–MS/MS harnesses the unparalleled analytical power of tandem mass spectrometry, enabling unequivocal identification and quantification of targeted peptides amidst an ocean of background proteins. The marriage of selective immunoaffinity capture with mass spectrometric detection creates a synergistic effect, dramatically improving sensitivity for low-abundance analytes like amylin. This strategy surpasses typical antibody-based enrichment methods, leveraging the specificity of engineered protein binders with the analytical rigor of mass spectrometry, thereby paving the way for next-generation diagnostic assays.

Despite these promising early results, the authors candidly acknowledge current limitations in recovering endogenous amylin directly from patient samples. The endogenous concentrations are sufficiently low that even with the optimized binder, reliable detection remains elusive. This caveat propels future research trajectories toward evolving tighter-binding variants of amylin-68nαβ through iterative rounds of protein engineering and affinity maturation. Enhanced binders with nanomolar or subnanomolar dissociation constants will be pivotal for detecting physiological levels of amylin without the need for artificial spiking.

Beyond amylin, this methodology demonstrates a broader paradigm shift in developing protein binders against intrinsically disordered proteins (IDPs), a notoriously challenging class for traditional antibody development. The diffusible nature of the amylin binder exemplifies innovative strategies to target flexible protein conformers, expanding the toolkit available for biomarker discovery. Such advances resonate deeply within the fields of neurodegeneration, cancer, and metabolic diseases, where IDPs play critical pathogenic roles yet remain poorly exploitable by conventional immunoassays.

Technically, the research capitalizes on the exquisite balance between binder affinity and kinetic on/off rates, ensuring sufficient capture of analytes during limited incubation times without compromising elution efficiency. This kinetic tuning is essential to maintain throughput in clinical laboratories while preserving assay reproducibility. Furthermore, the conjugation chemistry linking amylin-68nαβ to magnetic beads involves stable covalent attachment strategies optimized to retain binder conformational integrity and accessibility of binding sites, crucial for maintaining enrichment performance over multiple assay cycles.

The choice of PBS–CHAPS as a simplified surrogate matrix reflects an astute approach to dissect binder interactions free from protein interference inherent in plasma or serum. CHAPS, a zwitterionic detergent, preserves protein solubility and native conformations, simulating physiological conditions in a controlled environment. Such surrogate systems afford valuable insights into fundamental binder-peptide affinity without confounding matrix effects, offering a platform for rational binder improvement.

Looking ahead, the seamless integration of improved amylin binders with multiplexed LC–MS/MS instruments holds promise for clinical adoption. Routine assays capable of quantifying multiple peptides simultaneously with high precision would transform patient stratification and monitoring, particularly in metabolic disorders like diabetes where amylin dynamics are closely intertwined with disease progression. Moreover, such refined detection tools could unravel hitherto inaccessible biological insights by enabling reliable quantitation of transient or low-abundance IDP biomarkers.

The implications extend further into drug development pipelines where target engagement and pharmacodynamics of novel therapeutics directed at amylin or related IDPs require sensitive readouts. Immunoaffinity enrichment employing engineered binders aligned with mass spectrometry detection offers unparalleled specificity and quantitative accuracy, bridging a critical gap in translational research. This cross-disciplinary technology exemplifies the power of protein engineering coupled with analytical chemistry to tackle medically relevant challenges.

Ultimately, this pioneering study elucidates a conceptual and technical foundation that may catalyze a new era in biomolecular measurement. The strategic harnessing of diffusible protein binders, exemplified by amylin-68nαβ, integrates seamlessly with advanced mass spectrometric methodologies to deliver sensitivity levels previously unattainable for disordered and low-abundance proteins in human serum. Such innovations herald transformative potential across biomedical research, diagnostics, and therapeutics by unlocking precise measurement capabilities for elusive molecular players.

By pushing the boundaries of protein capture chemistry and analytical instrumentation, the authors highlight a roadmap toward consistently monitoring biomolecules that defy classical detection paradigms. As affinity reagents and mass spectrometric platforms evolve in lockstep, one anticipates accelerated discovery pipelines and enhanced clinical outcome assessments. This landmark progress underscores the imperative for interdisciplinary collaboration at the interface of protein science and analytical technology to recreate windows into complex biological landscapes.

In conclusion, this meticulous work by Liu, Wu, Choi, and colleagues represents a seminal step forward in biomarker detection technology. Their exploration into amylin-68nαβ binder-mediated immunoaffinity enrichment coupled with LC–MS/MS establishes a versatile platform geared toward overcoming inherent limitations in analyzing intrinsically disordered and low-abundance proteins. Continued refinement and deployment of such innovations promise to reshape molecular diagnostics with broad-reaching implications for precision medicine.

Subject of Research:
The development and application of engineered protein binders for immunoaffinity enrichment combined with liquid chromatography–tandem mass spectrometry to detect low-abundance intrinsically disordered proteins, specifically focusing on amylin in human serum.

Article Title:
Diffusing protein binders to intrinsically disordered proteins

Article References:
Liu, C., Wu, K., Choi, H. et al. Diffusing protein binders to intrinsically disordered proteins. Nature (2025). https://doi.org/10.1038/s41586-025-09248-9

Image Credits:
AI Generated

Single-stranded DNA, while less prevalent than its double-stranded counterpart, plays a pivotal role in various biological functions and technologies. Found frequently in certain viruses, this form of DNA is integral to processes such as cell replication, repair, and has applications in sequencing, molecular diagnostics, and even nanotechnology. However, the existing limitations of tools focusing on single-stranded DNA have posed significant challenges for researchers aiming to exploit its full potential. Until now, a lack of endonucleases—enzymes that cut DNA—that exclusively target single-stranded sequences has hindered advancements in this area.

The Ssn endonucleases investigated by Veyrier’s team represent a substantial leap forward. By isolating and characterizing these enzymes from the bacterium Neisseria meningitidis, commonly known for its role in bacterial meningitis, the researchers noted that these endonucleases identify specific sequences within single-stranded DNA. The ability to recognize and cut at precise points not only opens new avenues for biological research but also addresses a critical gap in genetic engineering capabilities.

The specificity of the Ssn enzymes is particularly noteworthy. In the bacterium studied, it was found that the enzyme identifies a particular sequence essential for the exchange and modification of genetic material. This molecular recognition mechanism is crucial for driving evolutionary processes and enhancing genetic diversity within microbial populations. As Professor Veyrier articulates, the implications of such discoveries resonate beyond fundamental biology; they provide vital insights into bacterial evolution and adaptation.

Moreover, this research has unearthed thousands of analogous enzymes within this newly identified family. The breadth of the Ssn enzyme family emphasizes how many organisms may possess similar capabilities to manipulate their genetic material. The implications for biotechnology are vast; with the knowledge that such enzymes are widespread, scientists can begin to harness these tools for varying applications across medicine and agriculture.

From a medical standpoint, the potential benefits of these new enzymes could be transformative. By enabling more precise genetic manipulations, researchers could enhance current gene editing technologies, leading to breakthroughs in treating both acquired and hereditary diseases. The prospect of developing refined tools for DNA detection and molecular diagnosis could significantly improve our ability to identify and understand diseases at the genetic level.

The Ssn endonucleases can also contribute to the detection and manipulation of DNA in a multitude of contexts. This could include identifying pathogens in clinical settings, which is critical for the timely treatment of infections. The enhanced accuracy and efficiency afforded by these enzymes may improve diagnostics, offering quicker and more reliable results when it comes to understanding genetic diseases or infections.

Furthermore, the versatility of these enzymes extends to industrial biotechnology, where they could be employed in various applications, including bioengineering and synthetic biology. As we delve deeper into the understanding of genetic systems, tools like the Ssn endonucleases could facilitate innovation across different fields, from sustainable agriculture to pharmacy.

Amidst these exciting developments, the INRS research team has taken steps to ensure this discovery is protected with a pending patent, signaling the potential for commercial viability. The evolution of these enzymes into practical applications necessitates collaboration across academic and industrial fields to fully realize their benefits.

The study surrounding these Ssn enzymes and their capabilities has already made waves in the scientific community, receiving publication in a reputable journal, Nature Communications. This recognition not only underscores the significance of the findings but also encourages further exploration into how such enzymes can be integrated into existing technologies and what other functionalities they may possess.

In conclusion, the identification of this new family of Ssn endonucleases capable of targeting single-stranded DNA marks a pivotal moment in the trajectory of genetic manipulation. These enzymes could redefine many aspects of biotechnology, enhancing current methodologies in gene editing and diagnostics, while also paving the way for future innovations. The research spearheaded by Professor Veyrier and his team suggests that we are just scratching the surface of what is possible within the realm of genetic engineering, and it is an exciting time for scientists eager to explore these new frontiers.

This breakthrough discovery exemplifies how persistent research in microbial genetics can yield technologies with wide-ranging implications, reminding us how much we still have to learn about the fundamental principles that govern life at the molecular level.

Subject of Research:
Article Title: New tool for cutting DNA: promising prospects for biotechnology
News Publication Date: 14-Apr-2025
Web References: Nature Communications
References: Chenal, M., Rivera-Millot, A., Harrison, L.B. et al. Discovery of the widespread site-specific single-stranded nuclease family Ssn. Nat Commun 16, 2388 (2025). DOI link
Image Credits: Ella Maru Studio

Keywords

CRISPR, Ssn endonucleases, single-stranded DNA, gene editing, biotechnology, Neisseria meningitidis, molecular diagnostics, genetic manipulation, evolutionary biology.